Selenium Treatment Effect in Auto-Immune Hashimoto Thyroiditis in Macedonian Population

Nevena Manevska\textsuperscript{a, b}, Sinisa Stojanoski\textsuperscript{a}, Tanja Makazlieva\textsuperscript{a}

Abstract

Background: Selenium (Se), a necessary trace mineral for humans, has the highest concentration in the thyroid gland and is known of its anti-oxidant and anti-inflammatory properties. Many studies have reported that Se has a close relationship with auto-immune Hashimoto’s thyroiditis (HT), characterized by the presence of anti-thyroid peroxidase (aTPO) auto-antibodies.

Methods: Five hundred thyroid patients, males and females, mean age 46 ± 19 years, with diagnosed HT, were included in the study. Euthyroid forms of HT were treated with Se only, while patients with thyroid-stimulating hormone (TSH) > 10 µIU/mL were treated with both substitutional therapy of levothyroxine and Se.

Results: In around 37% of the patients treated with Se 3 × 50 µg/day with aTPO > 1,000 IU/mL, aTPO remained unchanged after 12 months, while 24.16% had aTPO < 500 IU/mL and 38.20% had aTPO between 500 and 1,000 IU/mL. Eighty-three out of 150 (55.33%) patients treated with Se 2 × 50 µg/day with aTPO between 500 and 1,000 IU/mL responded. More than half of the patients (91/172, 52.90%) with aTPO < 500 IU/mL treated with Se 50 µg/day normalized in 1 year. In euthyroid group of patients, 12 months after treatment with levothyroxine and Se, 47.18% were responders with aTPO > 1,000 IU/mL. In euthyroid group (Se only), the biggest response (30.56%) was seen in patients with the highest titer of aTPO > 1,000 IU/mL.

Conclusion: Se treatment is effective in reducing the levels of aTPO in patients with HT, alone or in combination with levothyroxine. This is due to the anti-inflammatory and anti-oxidant effect of Se. Our study promotes the concept of Se treatment in patients with euthyroid or hypothyroid state, with increased titers of aTPO.

Keywords: Selenium; Hashimoto thyroiditis; Thyroid; aTPO

Introduction

Selenium (Se) is an essential trace element that is required for the correct functioning of the immune system, naturally present in many foods, including Brazil nuts, organ meat, muscle meat, cereals, shellfish and fish and available as a dietary supplement, with a recommended daily intake for adults of 55 µg [1]. It exists in two forms: inorganic (selenate and selenite) and organic (selenomethionine and selenocysteine). In human tissues, the most common form is selenomethionine, where it can be incorporated nonspecifically with the amino acid methionine in body proteins. Skeletal muscle is the major site of Se storage (approximately 28-46% of the total Se pool) [2].

Se, a necessary trace mineral for humans, has the highest concentration in the thyroid gland and is known of its anti-oxidant and anti-inflammatory characteristics [3]. Hormones and growth factors regulate the expression of selenoproteins and conversely, Se supply modulates hormone actions. At least 30 proteins are Se-dependent, including glutathione peroxidase enzyme, iodothyronine deiodinases enzyme (converting thyroxine to bioactive 3-iodothyronine) and thioredoxin reductases (TRs) [4], which implies that individuals with Se deficiency will further on be closely associated with thyroid damage and lymphocytic inflammation. Many studies have reported that Se has a close relationship with auto-immune Hashimoto’s thyroiditis (HT), characterized by the presence of anti-thyroid peroxidase (aTPO) auto-antibodies. The therapeutic effect of Se supplementation in HT treatment remains unclear.

The objective of the present study was to determine the efficacy of Se supplementation for the treatment of HT.

Materials and Methods

A prospective longitudinal randomized interventional study was performed at the outpatient’s thyroid unit of the Institute of Pathophysiology and Nuclear Medicine in Skopje. The study was conducted in compliance with the Ethical Standards of the responsible institution on human subjects as well as with the Helsinki Declaration. We enrolled 500 consecutive thyroid patients, both males and females, at ages of 19 - 78 years, mean age 46 ± 19 years, with diagnosed HT, determined by ultrasonographic features of the thyroid gland and elevated level of aTPO (10.0 - 35.0 IU/mL). Standard laboratory tests were investigated, such as the level of free thyroxine (FT\textsubscript{4}),
thyroid-stimulating hormone (TSH) and aTPO (immunochemiluminescent method was used, with Immulite 2000). The ultrasonographic examination was performed by three observers individually, all with over 10 years of experience in the field of thyroid gland ultrasonography, and gland volume and change in the echogenicity in correlation with aTPO levels were analyzed. The ultrasonography was performed using linear sonde for small organs, with frequency of 7.5 - 10 MHz (LN 12-3, Philips HD6).

The inclusion criteria were: patients with euthyroid function (TSH: 0.4 - 4.5 µIU/mL; FT4: 11.0 - 25.0 pmol/L; FT3: 2.8 - 6.5 pmol/L), with positive aTPO; patients with subclinical hypothyroid function (TSH: 4.5 - 10 µIU/mL, normal or low values for FT4 and FT3) with positive aTPO; patients with hypothyroid function (TSH > 10 µIU/mL, low values for FT4 and FT3) with positive aTPO.

The exclusion criteria were: patients with hyperthyroid function and positive aTPO; patients treated with drugs that interfere with thyroid function and pregnancy in the last 12 months before enrolment.

Se treatment

All patients were treated with increasing Se therapy, according to the levels of elevation of atTPO: 1) Patients with titer of atTPO > 1,000 IU/mL were treated with three tablets/day (150 µg Se); 2) Patients with titer of atTPO between 500 and 1,000 IU/mL were treated with two tablets/day (100 µg Se); 3) Patients with titer atTPO between 50 and 500 IU/mL were treated with one tablet/day (50 µg Se).

Patients who showed normal values of the TSH (n = 181, 36%) (euthyroid form of HT) as well as those that presented as subclinical form of hypothyrosis were treated with Se only, while patients with TSH > 10 (n = 319, 64%) were treated with both substitutional therapy of levothyroxine (LT4) plus Se therapy. We evaluated the changes in the level of atTPO and also the volume and changes in the ultrasonographic features in a 1-year period duration of treatment.

Results

Regarding the thyroid status of the patients, out of 500 patients, 178 (36%) presented with atTPO > 1,000 IU/mL, 150 (30%) had atTPO between 500 and 1,000 IU/mL and 172 (34%) had atTPO < 500 IU/mL. Around 37% of patients with initial value of atTPO > 1,000 IU/mL, treated with Se 3 × 50 µg/day, showed treatment effect after the first 3 months of the treatment: 10/178 (5.62%) lowered the titer of atTPO below 500 IU/mL, and 56/178 (31.46%) had atTPO between 500 and 1,000 IU/mL. But at the end of the treatment (after 12 months) in only 67/178 (37.64%) aTPO remained unchanged, while 43/178 (24.16%) had aTPO < 500 IU/mL and 68/178 (38.20%) had aTPO between 500 and 1,000 IU/mL (P < 0.04) (Fig. 1).

From 150 patients with the initial value of aTPO between 500 and 1,000 IU/mL, treated with Se 2 × 50 µg/day, treatment effect with aTPO < 500 IU/mL was registered in 39 (26%) patients in the first 3 months of treatment, 48 (32%) in the period of 3 - 6 months after treatment, 64 (42.67%) 6 - 9 months after treatment and 83 (55.33%) 1 year after treatment (Fig. 2). More than half of the patients (91/172, 52.90%) who had aTPO < 500 IU/mL and were treated with Se dose of 50 µg/day normalized in a period of 1 year (P < 0.02) (Fig. 3).

Mainly patients that had high titer of aTPO > 1,000 IU/mL (n = 142, 44.50%), or aTPO in the range of 500 - 1,000 IU/mL (n = 101, 31.66%) suffered also from hypothyroidism, while the highest percent of the euthyroid patients (n = 96, 53.03%) had lower titer of aTPO < 500 IU/mL (P < 0.03) (Fig. 4).

In the hypothyroid group of patients treated with both levothyroxine and Se, we evaluated the response of this combination of therapy in a period from 3 months interval up to 12 months interval after treatment. We demonstrated significantly lower titer of aTPO in the group of patients with the initial level of aTPO > 1,000 IU/mL (n = 142 at initial phase, n = 67 after 12 months, 47.18% responded), as well as in the group
with the initial level of aTPO between 500 and 1,000 IU/mL (n = 101 at initial phase, n = 80 after 12 months, 79.20% responded) (Fig. 5).

In the euthyroid group of patients (n = 181, 36.2%) treated...
with Se therapy only, we also found significant lowering of the titer of aTPO. In the subgroup with aTPO > 1,000 IU/mL, 25/36 (69.44%) remained with high aTPO > 1,000 IU/mL, while 30.56% responded after 1 year of Se treatment. Despite this, very small percent of response was noticed in the other two subgroups: only 4.05% responded with aTPO between 500 and 1,000 IU/mL, the same as at the initial phase, and 7.29% responders were seen with initial titer of aTPO < 500 IU/mL (P < 0.03) (Fig. 6).

In the age group above 50 years, when the initial titer of aTPO was above 1,000 IU/mL (n = 108, 21.6%) or between 500 and 1000 IU/mL (n = 65, 13%), we found significantly lower titer of aTPO, in the follow-up period of 12 months, 41.67% and 46.15% responded, respectively. Very good response of lowering the titer of aTPO was seen in the age group of 30 - 50 years. In this group, 16/30 (53.33%) remained with aTPO level after selenium + levothyroxine administration in the hypothyroid group. aTPO: anti-thyroid peroxidase.

Figure 5. aTPO level after selenium + levothyroxine administration in the hypothyroid group. aTPO: anti-thyroid peroxidase.

In the age group above 50 years, when the initial titer of aTPO was above 1,000 IU/mL (n = 108, 21.6%) or between 500 and 1000 IU/mL (n = 65, 13%), we found significantly lower titer of aTPO, in the follow-up period of 12 months, 41.67% and 46.15% responded, respectively. Very good response of lowering the titer of aTPO was seen in the age group of 30 - 50 years. In this group, 16/30 (53.33%) remained with aTPO level after selenium administration in the euthyroid group. aTPO: anti-thyroid peroxidase.

Figure 6. aTPO level after selenium administration in the euthyroid group. aTPO: anti-thyroid peroxidase.

In the age group above 50 years, when the initial titer of aTPO was above 1,000 IU/mL (n = 108, 21.6%) or between 500 and 1000 IU/mL (n = 65, 13%), we found significantly lower titer of aTPO, in the follow-up period of 12 months, 41.67% and 46.15% responded, respectively. Very good response of lowering the titer of aTPO was seen in the age group of 30 - 50 years. In this group, 16/30 (53.33%) remained with aTPO level after selenium administration in the euthyroid group. aTPO: anti-thyroid peroxidase.

Figure 6. aTPO level after selenium administration in the euthyroid group. aTPO: anti-thyroid peroxidase.

Figure 7. Age in correlation with aTPO level. aTPO: anti-thyroid peroxidase.
the initial value of aTPO > 1,000 IU/mL, while 46.67% responded. Patients who had initial value of aTPO between 500 and 1,000 IU/mL, 66.67% remained the same, while 33.33% responded (after 1 year had lower levels of aTPO). Very low percentage of response (17.02%) was seen in this age group with aTPO < 500 IU/mL, while 39/47 (82.98%) were non-responders (Fig. 7).

All patients had thyroid ultrasound imaging suggestive of chronic thyroiditis with typical hypoechogenicity. Taking into account the thyroid volume, we found that atrophy of the thyroid was more associated in the group with the lowest titer of aTPO < 500 IU/mL, while those with highest titer of aTPO > 1,000 IU/mL had enlarged thyroid volume.

Discussion

In view of the pivotal role of Se in thyroid physiology, it is conceivable that Se supplementation may be of benefit to patients with HT, particularly in clinical situations of Se deficiency [5]. Several studies have suggested that Se treatment reduces antibodies levels, allows lower dosage of LT₄ supplementation and may provide other beneficial effects in patients with HT.

Interest in interactions between Se and iodine deficiency first arose in 1980's from the discovery that Se is essential for normal thyroid hormone metabolism. It was first recognized as an elevated plasma thyroidoxine (T₄) concentration and a decreased plasma 3,3′,5 triiodothyronine (T₃) concentration in Se-deficient animals [6, 7]. Few years later, when children in Central Africa with iodine and Se deficiencies were supplemented with Se alone, it was discovered that thyroid destruction and myxedematous cretinism was developed, suggesting that Se should not be supplemented prior to correction of the iodine deficit [8].

Se plays a key role in the thyroid cell physiology, incorporated in the molecular structure of several enzymes like glutathione peroxidase, critically involved in protecting the gland against oxidative damage, as well as degradation of H₂O₂ to water and the other important enzyme is iodothyronine deiodinases involved in producing active form of thyroid hormones. TPO catalyzes the biosynthesis of thyroid hormones and is a major auto-antigen in Hashimoto’s disease. Hydrogen peroxide (H₂O₂) is a substrate in catalyzing the iodination and coupling of tyrosyl residues in thyroglobulin to produce thyroid hormone. Furthermore, as a free radical, it is capable of inflicting oxidative damage. Se deficiency contributes to improper function of these two enzymes, thus resulting in ineffective production of T₃, inefficient protection against free radicals, and further on facilitating cell damage and auto-immune gland destruction [4].

We performed a prospective, randomized, longitudinal, interventional study to assess the effects of Se supplementation for HT. We have similar number of the patients in the three groups of aTPO: 36% had aTPO > 1,000 IU/mL, 34% had aTPO < 500 IU/mL, while around 30% had titer between 500 and 1,000 IU/mL. We detected nearly 50% or more response in each of the three groups treated with Se: 63% lowering the titer of aTPO < 500 IU/mL if treated with Se 3 × 50 µg/day, 55.33% lowering of aTPO if treated with Se 2 × 50 µg/day and lowering or normalizing the aTPO levels in nearly 53% if treated with Se 50 µg/day. Consecutive lowering of the aTPO level was noticed in every following 3 months up to 12 months, thus increasing the number of patients with titer below 500 IU/mL. This indicated that at least nearly 1 year is needed for and in-depth assessment of Se treatment in HT.

Observational period of 1 year was used by Mazokopakis et al who prospectively studied 80 women with HT orally treated with 200 µg Se (40 treated during a 6-month period and 40 patients treated for 1 year). They showed significant reduction of serum aTPO levels during the first 6 months (by 5.6% and 9.9% at 3 and 6 months, respectively). The continuation of Se supplementation up to 1 year resulted in an additional 8% decrease of aTPO compared with the basal values, while the cessation caused a 4.8% increase in the aTPO concentrations [9].

Some studies evaluated Se effect only in 3-month or 6-month periods. In the study of Toulis et al significantly lower aTPO titers were demonstrated after only 3 months Se supplementation (four studies, random effects weighted mean difference: -271.09, 95% confidence interval: -421.98 to -120.19, P < 0.0001), and improvement in mood and/or general well-being was noted (three studies, random effects risk ratio: 2.79, 95% confidence interval: 1.21 - 6.47, P = 0.016) when compared with controls. They have concluded that different pattern of response to Se supplementation was associated with the baseline aTPO titers in HT that can be used to identify which patients would benefit most from treatment [5].

Positive effect of Se therapy was described in the study of Turker et al. Oral administration of 200 µg Se/day for 3 months effectively decreased serum aTPO titers (from 803.9 ± 83.8 to 572.3 ± 17.3 IU/mL, 26.2% decrement, P < 0.001), while in the placebo group, there was insignificant change (from 770.3 ± 66.2 to 773.4 ± 72.9 IU/mL, P > 0.05). These authors found out that lower supplementation dose of Se (100 µg/day) showed increase in aTPO for 38.1%, while supplementation of 200 µg/day showed decrease of aTPO for 26.2% in the first 6 months [10].

In a blinded, placebo-controlled trial, Gartner et al observed that in the group of HT females receiving 200 µg (2.53 μmol) sodium selenite per day, orally for 3 months, the mean aTPO concentration decreased significantly (63.6% vs. 88% in the placebo group) [11].

Similarly, a study conducted by Zhu et al in 2012 on autoimmune thyroiditis patients with different thyroid functional status revealed that Se supplementation with 200 µg for 6 months resulted in the reduction of aTPO concentration (12.6% in subclinical and 20.4% in the overt form of the disease) [12].

In 2003, Duntas et al performed a randomized, placebo-controlled prospective study to investigate the effects of Se treatment on 65 patients with auto-immune thyroiditis. They divided the patients in two groups, group I (n = 34) was treated with Se 200 µg, plus LT₄, whereas group II (n = 31) received LT₄ plus placebo over a period of 6 months. No significant difference was noted between groups, although there was a decrease of 46% at 3 months and 55.5% at 6 months in group I vs. 21% and 27% respectively in group II [13].

In our study, we also evaluated the link between the age
and the titer of aTPO. The highest titer of aTPO was associated
with younger patients, while older patients had lowest titer
(aTPO < 500 IU/mL). No relationship was found between the
age and the response rate to the treatment in the study of Turk-
er. Thus, treatment should be started at an early age to save
more thyrocytes, otherwise, it may be ineffective in atrophic
phase of the pathology. They have also noted sharp decrease in
serum aTPO levels at the beginning of Se treatment, in patients
with relatively high serum titers [10].

TPO is a poorly glycosylated intracellular microsomal antigen, membrane-bound enzyme, responsible for iodine (I
) oxidation and iodination of tyrosyl residues of the Tg mole-
cule [14]. Polyclonal antibodies from healthy individuals and
patients are directed against the epitopes. Destruction of the
thyrocytes > 90% leads to hypothyroidism and thus higher lev-
els of antibodies against Tg and TPO promote progression to
hypothyroidism [15].

Regarding the patient status, more significant lowering of
the aTPO titer from the initial point was found in the hypothy-
roid group of patients vs. euthyroid. The effect of Se is already
evaluated in several studies, although in a smaller group of
patients.

So far in the literature we have not found an article that
divided the patients in groups regarding the titer of aTPO and
in that way ordinate the dose of Se. Usually total Se dose per
day ranged from 150 to 200 µg. We have used lower dose of
Se where aTPO was lower, while as it increased we increased
the therapeutic dose of Se, with starting point of 50 µg up to
150 µg. Lower doses of Se were used in a prospective study
by Nacamulli et al. They revealed reduced echogenicity of the
thyroid and lower levels of aTPO and aTg, using supplemen-
tation with physiological doses of Se (80 µg/day of sodium
selenite) for 12 months, without significantly affecting the con-
centration of TSH or T₄ [16].

Moreover, the pharmacokinetics of selenomethionine
were studied in 10 patients and eight volunteers at baseline and
2, 4, 6 and 24 h after oral administration of a 200 µg tablet of
selenomethionine. Finally, Se levels were measured at the end
of the study in some patients of both groups and their results
were correlated with thyroid hormone levels [15].

According to the Polish research, the average content of
Se in serum of patients with Hashimoto disease (63.03 ± 17.31
µg/L) was significantly lower (P < 0.0007) in comparison with
the control group (75.16 ± 19.92 µg/L) [17]. Similarly, Erdal
et al revealed lower levels of Se in serum of patients with HT
(67.7 ± 10.4 mg/L) as compared to the control group (83.7 ±
17.3 mg/L) [18].

The role of Se supplementation to restore euthyroidism in
at least one-third of subclinical hypothyroid patients with auto-
immune thyroiditis was observed by Pirola in 2016. From 192
patients, one group received 83 µg Se/day orally for 4 months,
and the others were controls who did not receive any treat-
ment. At the end of the study, 33/192 (17.2%) participants
restored euthyroidism, that was significantly more frequent
among treated patients vs. controls (30/96 (31.3%) vs. 3/96
(3.1%), P < 0.0001) [19].

Unresponsiveness of many HT patients to Se therapy is
interesting. The cohort study carried out by Karanikas et al
in 2008 demonstrated that Se administration in HT patients
did not induce significant immunological changes, in terms of
aTPO levels (524 ± 452 vs. 505 ± 464 IU/mL; P > 0.05) [20].
Although we can find in the literature some studies that show
no improvement in the aTPO level despite Se treatment, still
more long-term, randomized controlled, multicenter trials are
needed to evaluate the beneficial effects of the Se supplemen-
tation in HT patients.

Conclusion

The results of our study demonstrate, as in the literature find-
ings, that at present, there is a benefit of the use of Se sup-
plementation for the treatment of patients with HT. Further-
more, well-designed randomized placebo-controlled trials on
Se treatment in HT are still needed and can be used in future
for clinical decision making.

Acknowledgments

Not applicable.

Financial Disclosure

We have nothing to declare.

Conflict of Interest

We have no conflict of interest.

Informed Consent

All patients had full filed informed consent for entering the
study.

Author Contributions

Nevena Manevska: patient selection and treatment, materials
and methods, discussion, results. Sinisa Stojanoski: patient
selection and treatment, materials and methods, results and
conclusion. Tanja Makazlieva: patient selection and treatment,
materials and methods, results.

References

Professional/#en3.
2. Terry EN, Diamond AM. Selenium. In: Erdman JW, Mac-
donald IA, Zeisel SH, eds. Present Knowledge in Nutri-
p. 568-587.
3. Drutel A, Archambeaud F, Caron P. Selenium and the